Everett Harris & Co. CA Sells 93 Shares of Danaher Co. (NYSE:DHR)

Everett Harris & Co. CA lowered its stake in shares of Danaher Co. (NYSE:DHR) by 0.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,849 shares of the conglomerate’s stock after selling 93 shares during the quarter. Everett Harris & Co. CA’s holdings in Danaher were worth $2,510,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Trueblood Wealth Management LLC purchased a new stake in Danaher during the fourth quarter valued at about $760,000. Successful Portfolios LLC lifted its holdings in Danaher by 6.5% during the fourth quarter. Successful Portfolios LLC now owns 1,107 shares of the conglomerate’s stock valued at $256,000 after purchasing an additional 68 shares during the last quarter. MJP Associates Inc. ADV lifted its holdings in Danaher by 10.6% during the fourth quarter. MJP Associates Inc. ADV now owns 4,601 shares of the conglomerate’s stock valued at $1,064,000 after purchasing an additional 442 shares during the last quarter. Great Lakes Retirement Inc. lifted its holdings in Danaher by 9.5% during the fourth quarter. Great Lakes Retirement Inc. now owns 33,036 shares of the conglomerate’s stock valued at $7,642,000 after purchasing an additional 2,878 shares during the last quarter. Finally, Well Done LLC lifted its holdings in Danaher by 32.6% during the fourth quarter. Well Done LLC now owns 2,986 shares of the conglomerate’s stock valued at $691,000 after purchasing an additional 734 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 0.4 %

Shares of DHR opened at $249.72 on Friday. The firm’s 50 day simple moving average is $247.17 and its 200 day simple moving average is $230.53. The company has a market capitalization of $184.72 billion, a P/E ratio of 39.08, a P/E/G ratio of 3.77 and a beta of 0.84. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $259.00.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The business had revenue of $6.41 billion for the quarter, compared to analysts’ expectations of $6.10 billion. During the same period last year, the business earned $2.87 earnings per share. The business’s quarterly revenue was down 10.2% on a year-over-year basis. Sell-side analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be given a dividend of $0.27 per share. This is a boost from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date is Wednesday, March 27th. Danaher’s dividend payout ratio (DPR) is presently 15.02%.

Insider Buying and Selling at Danaher

In other Danaher news, Director Teri List sold 3,289 shares of the stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the transaction, the senior vice president now owns 38,102 shares in the company, valued at $9,601,704. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Teri List sold 3,289 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the transaction, the director now owns 19,726 shares in the company, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Insiders have sold 32,957 shares of company stock worth $8,265,802 over the last ninety days. Insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on DHR shares. Royal Bank of Canada upped their price objective on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. TheStreet raised shares of Danaher from a “c+” rating to a “b-” rating in a report on Friday, December 8th. Raymond James increased their price target on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Finally, JPMorgan Chase & Co. increased their price target on shares of Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, December 20th. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $266.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.